Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|17|18|1818-1824

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.17, Iss.18, 2011-06, pp. : 1818-1824

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Expression of protein kinase C isoforms in cardiac hypertrophy and heart failure due to volume overload

By Sentex Emmanuelle   Wang Xi   Liu Xueliang   Lukas Anton   Dhalla Naranjan S.  

Canadian Journal of Physiology and Pharmacology, Vol. 84, Iss. 2, 2006-02 ,pp. : 227-238

NRC Research Press

Access to resources Recommend Favorite

The Role of PPARs in Pathological Cardiac Hypertrophy and Heart Failure

By  

Current Pharmaceutical Design, Vol. 23, Iss. 11, 2017-05 ,pp. : 1677-1686

Bentham Science Publishers

Access to resources Recommend Favorite

Vitamin D Therapy in Cardiac Hypertrophy and Heart Failure

By  

Current Pharmaceutical Design, Vol. 17, Iss. 18, 2011-06 ,pp. : 1794-1807

Bentham Science Publishers

Access to resources Recommend Favorite

The Phosphoinositide 3-Kinase Signaling Pathway as a Therapeutic Target in Grade IV Brain Tumors

By  

Current Cancer Drug Targets, Vol. 11, Iss. 8, 2011-10 ,pp. : 894-918

Bentham Science Publishers

Access to resources Recommend Favorite

Potential Treatment of Cardiac Hypertrophy and Heart Failure by Inhibiting the Sarcolemmal Binding of Phospholipase C&bgr;1b

By  

Current Drug Targets, Vol. 11, Iss. 8, 2010-08 ,pp. : 1032-1040

Bentham Science Publishers

Access to resources Recommend Favorite